Albany Molecular Research opens new facilities in Singapore and India
The Singapore subsidiary of global drug discovery company, Albany Molecular Research (AMR), has moved into new larger laboratories. New facilities for the group's Indian subsidiary in Hyderabad are also now operational.
The Singapore subsidiary of global drug discovery company, Albany Molecular Research (AMR), has moved into new larger laboratories. New facilities for the group's Indian subsidiary in Hyderabad are also now operational.
The Albany Molecular Research Singapore Research Centre was established in temporary facilities earlier this year while the new laboratories were under construction. The new facility can now accommodate over 50 scientists and capabilities there include medicinal chemistry support, custom synthesis of building blocks and scaffolds, as well as non-GMP scale up. AMR has an additional 29,000 sq ft of space at this facility and plans to add laboratories for cGMP synthesis and analytical chemistry, as well as additional facilities for chemical synthesis.
The laboratories of the Albany Molecular Research Hyderabad Research Centre hold up to 12 scientists and are being used for custom synthesis of scaffolds and building blocks, as well as preparation of reference standards.
A second laboratory for preparing up to kilogram quantities of pharmaceutical intermediates, starting materials and other compounds is currently under construction and expected to be operational by early next year. Together, the two laboratories in India are anticipated to accommodate up to 30 scientists.
Chairman, ceo and president Thomas D'Ambra, said: 'As we approach 2006, we look forward to further expansions in Singapore and India and the continued success of our global chemistry platform.'